Akorn Revenu
Quel est le Revenu de Akorn?
Le Revenu de Akorn, Inc. est $663.504M
Quelle est la définition de Revenu?
Le revenu est le revenu qu'une entreprise tire de ses activités commerciales normales, généralement de la vente de biens et de services aux clients.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Revenu des entreprises dans Health Care secteur sur OTC par rapport à Akorn
Que fait Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Entreprises avec revenu similaire à Akorn
- TIL a Revenu de ₨662.400M
- Ultra Petroleum a Revenu de $662.573M
- Ultra Petroleum a Revenu de $662.573M
- Perdoceo Education a Revenu de $662.846M
- Héroux-Devtek a Revenu de CAD$663.070M
- Movado a Revenu de $663.288M
- Akorn a Revenu de $663.504M
- Global Offshore Services a Revenu de ₨663.611M
- Cominar Real Estate Investment Trust a Revenu de CAD$663.771M
- Regal Real Estate Investment Trust a Revenu de HKD$664.120M
- Golub Capital BDC Inc a Revenu de $664.811M
- GitLab a Revenu de $665.218M
- Career Point a Revenu de ₨665.427M